艾塞那肽对肥胖2型糖尿病患者疗效观察  

作　　者：王祥香[1] 陈德志[1] 王昭玲[1] 火焱 蔡若男[1] 

机构地区：[1]江苏省徐州市第一人民医院内分泌科,221002

出　　处：《浙江临床医学》2012年第11期1347-1349,共3页Zhejiang Clinical Medical Journal

摘　　要：目的观察艾塞那肽对多种口服降糖药物联用和／或胰岛素联合治疗疗效不佳的肥胖2型糖尿病（T2DM）患者的临床疗效和安全性。方法选择对多种口服降糖药联用和／或胰岛素联合治疗疗效不佳的肥胖T2DM患者36例，在原有治疗基础上加用艾塞那肽治疗3个月。比较治疗前后的血糖、血脂、血压、体重及不良反应等指标。结果加用艾塞那肽治疗3个月后，患者的糖化血红蛋白Alc（HbAlc）、空腹血糖（FBG）、餐后2h血糖（2hPBG）、甘油三酯（TG）和体重均明显下降。主要的不良反应为胃肠道反应及低血糖，但两者均较轻微且短暂。结论对多种口服降糖药物联用和／或胰岛素联合治疗后血糖仍控制欠佳的肥胖2型糖尿病患者，艾塞那肽可有效控制血糖，并有助于体重的控制。Object To evaluate the efficacy and safety ofexenatide in obese patients with type 2 diabetes mellitus whose hyperglycemia is not adequately controlled despite treatment with oral hypoglycemic agents and insulin. Methods We identified 36 obese patients with type 2 diabetes mellitus initiating exenatide therapy in combination with other hypoglycemic agents used previously. All subjects＇ hyperglycemia is not adequately controlled despite treatment with oral hypoglycemic agents and insulin at baseline. Mean follow-up period was 3 months. The glucose level, lipid profiles, blood pressure, weight and adverse effect were recorded at baseline and 3 months. Results Hemoglobin Alc （ HbAlc ） , fasting blood glucose （ FBG ） 、postprandial blood glucose （ PBG ） , triglyceride （ TG ） and weight decreased significantly after treatment of exenatide 3 months later. The primary adverse effects were gastrointestinal events and hyperglycemia which were mild and transient. Conclusions Exenatide improves glucose control and causes weigh loss in obese patients with type 2 diabetes mellitus whose hyperglycemia is not adequately controlled despite treatment with oral hypoglycemic agents or insulin.

关 键 词：糖尿病 肥胖 艾塞那肽 

分 类 号：R587.1[医药卫生—内分泌]